Novo Nordisk, the Danish pharma heavyweight behind Ozempic, is feeling the squeeze as its once-booming diabetes drug sales ...

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...

Three new studies suggest that Ozempic and related diabetes and weight loss drugs may help protect the brain from strokes.

Novo Nordisk faces a sharp decline in sales of its injectable diabetes drugs, including Ozempic, due to intense competition ...

This potential loss of strength when taking Ozempic could be a particular concern for adults over the age of 60 who are at a higher risk of muscle loss and reduced mobility.

The outgoing chief executive of Novo Nordisk has revealed plans to ramp-up cost cutting 'efficiencies' across the business, ...

Muscle and strength loss in human aging, also known as sarcopenia, can result in trouble with balance and walking, according ...

When people were randomised to receive either a placebo or Ozempic, they became biologically younger with the latter drug ...

Copenhagen: Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second quarter net profit Wednesday, but rising ...

Cosmetic surgeons are reporting a growing number of patients with sagging skin and facial hollowing after losing weight with ...

Ozempic can cause loss of body weight that isn’t fat, raising concerns that the drug lowers muscle mass and strength. New ...

Despite this, one in five young adults who meet the criteria for the drugs are uninsured and one-third denied having a routine place for healthcare.